Nicolas H. Garcia
Research Subjects
Nicolas H. Garcia has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Devra J. Olson
Pfizer, Inc., Bothell, Washington
11 shared publications - Rebecca Mazahreh
Pfizer, Inc., Bothell, Washington
11 shared publications - Christopher M. Carosino
Pfizer, Inc., Bothell, Washington
10 shared publications - David J. Ortiz
Pfizer, Inc., Bothell, Washington
10 shared publications - Eliana Moskovitz
Pfizer, Inc., Bothell, Washington
10 shared publications - Hamidreza Ardalani
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
10 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 1 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Non–muscle-invasive bladder cancer (NMIBC) accounts for 75% of all new bladder cancer diagnoses. Despite new therapeutic treatment options aiming to replace Bacillus Calmette–Guérin (BCG), the standard of care for 40+ years, high rates of failure and recurrence of disease remain in patients with NMIBC. Integrins are a large family of cell surface receptors involved in key biological processes such as cellular adhesion, motility, and cytokinesis, and integrin β-6 (IB6) has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. IB6 is being actively tested in lung cancer with the antibody–drug conjugate (ADC) sigvotatug vedotin. In this study, we introduce PF-08052667, an IB6-directed ADC that has been optimized for local delivery via intravesical dosing in patients with NMIBC. PF-08052667 leverages the high and consistent expression of IB6 in NMIBC tumors for efficient ADC internalization. In PF-08052667, an average of 8 monomethyl auristatin E molecules are attached to an IB6-specific humanized IgG1 antibody via a glucuronide linker shown to increase potency in vitro. PF-08052667 efficacy was further optimized when administered after a bladder prewash, which improved ADC delivery to the bladder tissue. The combination of highly potent PF-08052667 with bladder prewash demonstrated enhanced in vivo efficacy while maintaining minimal systemic exposure and no systemic toxicity. Together, the results position PF-08052667 as a potential first-in-class ADC optimized for intravesical delivery and support further clinical examination in an ongoing phase I trial testing safety and efficacy in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Non–muscle-invasive bladder cancer (NMIBC) accounts for 75% of all new bladder cancer diagnoses. Despite new therapeutic treatment options aiming to replace Bacillus Calmette–Guérin (BCG), the standard of care for 40+ years, high rates of failure and recurrence of disease remain in patients with NMIBC. Integrins are a large family of cell surface receptors involved in key biological processes such as cellular adhesion, motility, and cytokinesis, and integrin β-6 (IB6) has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. IB6 is being actively tested in lung cancer with the antibody–drug conjugate (ADC) sigvotatug vedotin. In this study, we introduce PF-08052667, an IB6-directed ADC that has been optimized for local delivery via intravesical dosing in patients with NMIBC. PF-08052667 leverages the high and consistent expression of IB6 in NMIBC tumors for efficient ADC internalization. In PF-08052667, an average of 8 monomethyl auristatin E molecules are attached to an IB6-specific humanized IgG1 antibody via a glucuronide linker shown to increase potency in vitro. PF-08052667 efficacy was further optimized when administered after a bladder prewash, which improved ADC delivery to the bladder tissue. The combination of highly potent PF-08052667 with bladder prewash demonstrated enhanced in vivo efficacy while maintaining minimal systemic exposure and no systemic toxicity. Together, the results position PF-08052667 as a potential first-in-class ADC optimized for intravesical delivery and support further clinical examination in an ongoing phase I trial testing safety and efficacy in BCG-unresponsive and BCG-exposed NMIBC (NCT07206225).
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Representative analytical results for PF-0805266
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Representative analytical results for PF-0805266
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Intracellular trafficking and localization of PF-08052667
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Intracellular trafficking and localization of PF-08052667
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Saturation binding analysis of h2A2 antibody and PF-08052667 on UMUC3 parental and engineered cell lines
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
Saturation binding analysis of h2A2 antibody and PF-08052667 on UMUC3 parental and engineered cell lines
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
1B6 expression and efficacy on patient-derived organoids (PDOs)
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
1B6 expression and efficacy on patient-derived organoids (PDOs)
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
SW780 mouse model plots of individual mice
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
SW780 mouse model plots of individual mice
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
UMUC3-1B6+RL+ mouse model plots of individual mice and CR rates
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from An Integrin β6–Targeted Antibody–Drug Conjugate Optimized for Intravesical Delivery to Treat Non–Muscle-Invasive Bladder Cancer
UMUC3-1B6+RL+ mouse model plots of individual mice and CR rates
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
PF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Open AccessPF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.